Exhibit
Number
Description of Document
10.59
Amendment #1 to the Development, Option and LicenseAgreement between the Registrant
and Biogen Idec International Holding Ltd. dated December 15, 2014. Portions of this
exhibit have been omitted and separately filed with the SECwith a request for confidential
treatment.
10.60
Research Collaboration, Option and LicenseAgreement between the Registrant and Janssen
Biotech Inc. dated December 22, 2014. Portions of this exhibit have been omitted and
separately filed with the SEC.
10.61
Amendment No.2 to the Collaboration, License and Development Agreement between the
Registrant andAstraZenecaAB dated October 15, 2014. Portions of this exhibit have been
omitted and separately filed with the SECwith a request for confidential treatment.
14.1
Registrant’s Code of Ethics and Business Conduct. (36)
21.1
List of Subsidiaries for the Registrant.
23.1
Consent of Independent Registered PublicAccounting Firm.
24.1
Power of Attorney. (28)
31.1
Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted
Pursuant to Section 302 of the Sarbanes-OxleyAct of 2002.
31.2
Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted
Pursuant to Section 302 of the Sarbanes-OxleyAct of 2002.
32.1
Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the
Sarbanes-OxleyAct of 2002.
99.2
Form of ConfidentialityAgreement. (8)
101
The following financial statements from the Isis Pharmaceuticals, Inc. Annual Report on
Form 10-K for the year ended December 31, 2014, formatted in Extensive Business
Reporting Language (XBRL): (i) consolidated balance sheets, (ii) consolidated statements of
operations, (iii) consolidated statements of stockholders’ equity, (iv) consolidated statements
of cash flows, and (v) notes to consolidated financial statements (detail tagged).
(1)
Filed as an exhibit to the Registrant’s Registration Statement on FormS-1 (No. 33-39640) or amendments thereto and
incorporated herein by reference.
(2)
Filed as an exhibit to Registrant’s Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2006.
(3)
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and incorporated
herein by reference.
(4)
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2009 and incorporated
herein by reference.
(5)
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2008 and incorporated
herein by reference.
(6)
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 1998 and incorporated
herein by reference.
(7)
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 1999 and incorporated
herein by reference.
(8)
Filed as an exhibit to the Registrant’s Registration Statement on FormS-3 (No. 333-71911) or amendments thereto and
incorporated herein by reference.
(9)
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and incorporated
herein by reference.
(10)
Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and incorporated
herein by reference.
(11)
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2004 and incorporated
herein by reference.
132
